Carl Zeiss Meditec AG has confirmed that Bronwyn Brophy O’Connor will assume the role of Chief Executive Officer on December 1, 2026. On the same date, she will join the Executive Board of Carl Zeiss AG with responsibility for the Medical Technology segment. Her appointment as successor to current CEO Andreas Pecher was first announced in May 2026. With the start date now confirmed, she will take over from Andreas Pecher, who has served as interim CEO since January 1, 2026.
The leadership change comes at a critical time for Carl Zeiss Meditec, a leading medical technology company focused on innovative technologies and application-oriented solutions for ophthalmology and microsurgery. Brophy O’Connor brings a wealth of international experience in customer-focused innovation and business transformation. She currently serves as CEO of the Vitrolife Group in Sweden, a global medtech company publicly listed on the NASDAQ Stockholm. Her background includes senior roles at Johnson & Johnson, Covidien, Medtronic, and Thermo Fisher Scientific, where she held positions such as President of the EMEA region and Global President of the Immunodiagnostics Division. Her extensive experience across different markets and segments is expected to be instrumental in advancing Carl Zeiss Meditec’s strategy and transformation.
“I am delighted to join Carl Zeiss Meditec and the ZEISS Group. The company combines deep scientific expertise, close customer relationships and a strong commitment to improving patient care. I look forward to working with our teams and customers to build on these strengths, advance innovation and successfully shape the next stage of the company’s transformation,” said Bronwyn Brophy O’Connor.
Peter Kameritsch, Chairman of the Supervisory Board of Carl Zeiss Meditec AG, commented, “With Bronwyn Brophy O’Connor, Carl Zeiss Meditec is gaining an internationally experienced medtech executive who will bring a strong customer and innovation perspective to the company. We wish her a great start.” Dr. Michael Bolle, Chairman of the Supervisory Board of Carl Zeiss AG, added, “We would like to thank Andreas Pecher, both for his temporary dual role as CEO of the ZEISS Group and interim CEO of Carl Zeiss Meditec AG, and for providing important momentum during this period. With her excellent skills, Bronwyn Brophy O’Connor will now be able to further advance the strategy and transformation of the Medical Technology segment forward and contribute to the success of the ZEISS Group.”
Effective December 1, 2026, the Management Board of Carl Zeiss Meditec AG will comprise Bronwyn Brophy O’Connor as CEO and Justus Wehmer as CFO. The Executive Board of Carl Zeiss AG will include Andreas Pecher (President and CEO), Stefan Müller (CFO), Bronwyn Brophy O’Connor (Head of the ZEISS Medical Technology segment), Sven Hermann (Head of the ZEISS Consumer Markets segment), Dr. Frank Rohmund (Head of the ZEISS Semiconductor Manufacturing Technology segment), and Dr. Marc Wawerla (Head of the ZEISS Industrial Quality & Research segment). This transition is expected to ensure continuity and drive further growth in the medical technology segment.
Bronwyn Brophy O’Connor’s appointment underscores Carl Zeiss Meditec’s commitment to innovation and customer-centric solutions. Her track record in business transformation and international markets positions her to lead the company through its next phase of development. For more information, visit the ZEISS newsroom or the Carl Zeiss Meditec website. The original release is available on NEWMEDIAWIRE.
